{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T21:40:08Z","timestamp":1751751608693,"version":"3.41.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T00:00:00Z","timestamp":1531785600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T00:00:00Z","timestamp":1531785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Public Health Research Foundation"},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17lk0201061h0002"],"award-info":[{"award-number":["17lk0201061h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00774-018-0942-z","type":"journal-article","created":{"date-parts":[[2018,7,17]],"date-time":"2018-07-17T15:44:28Z","timestamp":1531842268000},"page":"491-495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04"],"prefix":"10.1007","volume":"37","author":[{"name":"Adequate Treatment of Osteoporosis (A-TOP) research group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3013-7775","authenticated-orcid":false,"given":"Yukari","family":"Uemura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhiko","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Tsukiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruki","family":"Sone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Soen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hagino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitsugu","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Orimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Shiraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,17]]},"reference":[{"key":"942_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1532-5415.2000.tb02641.x","volume":"48","author":"KE Ensrund","year":"2009","unstructured":"Ensrund KE, Thompson DE, Cauley JA, Nevitt MC, Kado DM, Hochberg MC, Santora AS, Black DM (2009) Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. J Am Geriat Soc 48:241\u2013249","journal-title":"J Am Geriat Soc"},{"key":"942_CR2","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1359\/jbmr.070412","volume":"22","author":"ND Nguyen","year":"2007","unstructured":"Nguyen ND, Center JR, Eisman JA, Nguyen TV (2007) Bone loss, weight loss, and weight fluctuation predict mortality risk in elderly men and women. J Bone Miner Res 22:1147\u20131154","journal-title":"J Bone Miner Res"},{"key":"942_CR3","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s00198-009-1121-9","volume":"21","author":"M Shiraki","year":"2010","unstructured":"Shiraki M, Kuroda T, Shiraki Y, Aoki C, Sasaki K, Tanaka S (2010) Effects of bone mineral density of the lumbar spine and prevalent vertebral fractures on the risk of immobility. Osteoporos Int 21:1545\u20131551","journal-title":"Osteoporos Int"},{"key":"942_CR4","doi-asserted-by":"publisher","first-page":"e3211","DOI":"10.1136\/bmj.e3211","volume":"344","author":"KE Poole","year":"2012","unstructured":"Poole KE, Compston JE (2012) Bisphosphonates in the treatment of osteoporosis. BMJ 344:e3211","journal-title":"BMJ"},{"key":"942_CR5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","volume":"296","author":"JE Dunford","year":"2001","unstructured":"Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Pulter CD, Ebetion FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296:235\u2013242","journal-title":"J Pharmacol Exp Ther"},{"key":"942_CR6","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00198-008-0816-7","volume":"20","author":"T Matsumoto","year":"2009","unstructured":"Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429\u20131437","journal-title":"Osteoporos Int"},{"key":"942_CR7","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00198-011-1782-z","volume":"23","author":"R Okazaki","year":"2012","unstructured":"Okazaki R, Hagino H, Ito M, Sone T, Nakamura T, Mizunuma M, Fukunaga M, Shiraki M, Nishizawa Y, Ohashi Y, Matsumoto T (2012) Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporos Int 23:1737\u20131745","journal-title":"Osteoporos Int"},{"key":"942_CR8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer GC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637\u2013645","journal-title":"JAMA"},{"key":"942_CR9","first-page":"351","volume":"15","author":"H Orimo","year":"2007","unstructured":"Orimo H (2007) The Japanese guidelines for the prevention and treatment of osteoporosis (2006 Edition). Osteoporos Japan 15:351\u2013355","journal-title":"Osteoporos Japan"},{"key":"942_CR10","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/BF00299308","volume":"55","author":"C Matsumoto","year":"1994","unstructured":"Matsumoto C, Kushida K, Yamazaki K, Imose K, Inoue T (1994) Metacarpal bone mass in normal and osteoporotic Japanese women using computed X-ray densitometry. Calcif Tissue Int 55:324\u2013329","journal-title":"Calcif Tissue Int"},{"key":"942_CR11","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1185\/03007995.2011.580341","volume":"27","author":"H Orimo","year":"2011","unstructured":"Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M, A-TOP (Adequate Treatment of Osteoporosis) research group (2011) Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT)-02. Curr Med Res Opin 27:1273\u20131284","journal-title":"Curr Med Res Opin"},{"key":"942_CR12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3143\/geriatrics.42.346","volume":"42","author":"K Toba","year":"2005","unstructured":"Toba K, Okochi J, Takahashi T, Kozo M, Nishinaga M, Yamada S, Takahashi R, Nishijima R, Kobayash Y, Machida A, Akishita M, Sasaki H (2005) Development of a portable fall risk index for elderly people living in the community. Nippon Ronen Igakkai Zasshi (Jpn J Geriatr) 42:346\u2013352","journal-title":"Nippon Ronen Igakkai Zasshi (Jpn J Geriatr)"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-018-0942-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-018-0942-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-018-0942-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T21:25:30Z","timestamp":1751750730000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-018-0942-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,17]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["942"],"URL":"https:\/\/doi.org\/10.1007\/s00774-018-0942-z","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"type":"print","value":"0914-8779"},{"type":"electronic","value":"1435-5604"}],"subject":[],"published":{"date-parts":[[2018,7,17]]},"assertion":[{"value":"1 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"YU has received a consultancy fee from Teijin Pharma. ST has received lecture fees from Astra-Zeneca, Taiho, and Ono. He has received consultation fees from DeNA Life Science and CanBus. He has received outsourcing fees from Satt and Asahi Kasei Pharma. His wife has been engaged in a research project of Bayer. TM and MT are employees of the Public Health Research Foundation. TS has received research grants from Asahi Kasei Pharma, Astellas Pharma, Daiichi-Sankyo, Taisho Toyama Pharmaceutical, Takeda Pharmaceutical, Pfizer and Teijin Pharma, and consulting fees from Daiichi-Sankyo and Takeda Pharmaceutical. AT received consultancy or lecture fees from Asahi Kasei, Teijin, Ono, Chugai, Takeda, and Daiichi-Sankyo pharma. SS received lecture and consultancy fees from Asahikasei Pharmaceutical Co., Astellas Pharma, Chugai Pharmaceutical Co., Daiichi Sankyo Co., Eisai Co., Eli Lilly Japan, Ono Pharmaceutical Co., Pfizer Co., Takeda Pharmaceutical Co. HH has received lecture and consultancy fees from Asahi Kasei Pharma Corp., Astellas Pharma Inc., MSD Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Pfizer Co., Ltd., Mitsubishi Tanabe Pharma Corp., Mochida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. ToS has received research grants from Astellas Pharma, Eisai, Daiichi-Sankyo, Chugai Pharmaceutical and Eli Lilly Japan as well as consulting and\/or lecture fees from Asahi Kasei Pharma, MSD and Daiichi-Sankyo. MF received consulting fees from Asahi Kasei Pharma and lecture fees from Daiichi-Sankyo, MSD, and Chugai Parma. HO received fees from Phizer co.jp. MS received lecture and consultancy fees from Asahikasei Pharma and Teijin Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}